

Electronic Supplementary Information

Ligand design for specific MHC class I molecules on the cell surface

Xizheng Sun^a, Reika Tokunaga^a, Yoko Nagai^a, Ryo Miyahara^a, Akihiro Kishimura^{a,b,c,d}, Shigeru Kawakami^e, Yoshiki Katayama^{a,b,c,d,f,g,*}, Takeshi Morij^{a,b,c,*}

^aGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.

^bDepartment of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.

^cCenter for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.

^dInternational Research Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.

^eDepartment of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.

^fCenter for Advanced Medical Innovation, Kyushu University, 744 Motooka, Nishi-Ku, Fukuoka 819-0395, Japan.

^gDepartment of Biomedical Engineering, Chung Yuan Christian University, 200 Chung Pei Rd., Chung Li, 32023 ROC, Taiwan.




Figure S1. Effect of concentration of peptide **1t** on the binding with RMA cells. Cells were treated with **1t** in serum-containing medium for 1 h at 37 °C. After washing three times with serum-free medium, cells were detected by image-based cytometer. The fluorescence intensity was not saturated in the examined concentration range (up to 40 μ M). Since we found that 0.8 μ M of peptide provided enough fluorescence to be detectable by fluorescence microscopy, we chose this concentration in most of the experiments.




Figure S2. Viability of cells after treatment of **1t** or **2t** (0.8 μM) (above), and after treatment of **1** or **2** (80 μM) (below). Cells were treated with each peptide in serum-containing medium for 1 h at 37 °C. After washing three times with serum-free medium, dead cells were stained with propidium iodide (PI) solution (2 μg/ml) (Sigma, St. Louis, USA) for 15 min on ice. The dead cells were counted by image-based cytometer.




Figure S3. Correlation of bound ligand peptide **2t** and cell surface expression of HLA A02:01. To stain HLA A02:01, cells were treated with FITC-labeled anti-HLA-A2 mAb (8 $\mu\text{g/ml}$) for 30 min at 4°C. The fluorescence intensity of FITC was quantified by flow cytometer (Cytoflex). The binding of **2t** with HLA A02:01 on the cell surface was conducted as follows. Cells were treated with **2t** (0.8 μM) in serum-containing medium for 1 h at 37°C, then washed three times with serum-free medium. The fluorescence intensity was quantified by image-based cytometer.




Figure S4. Evaluation of the specific binding of peptide-modified liposomes to RMA or T1 cells. Cells in group **L** were treated with 100 μ M of liposomes (containing no ligand peptide); cells in group **L1 + 1** and **L2 + 2** were preincubated with no-labeled peptides **1** or **2** (100 μ M) for 1 hour before adding the **L1** or **L2** liposomes (100 μ M, containing 3 μ M of ligand peptides) respectively. After washing three times with serum-free medium, cells were observed by confocal laser scanning microscopy. Blue and green color represent the nucleus and DiO-labeled liposome, respectively.







Figure S5. Molecular weight of the ligand peptides. The obtained peptides were identified by a matrix-assisted laser desorption ionization time-of-flight mass spectrometer (Bruker Daltonics, Billerica, MA, USA).



Retention time (min)




Figure S6. Chromatograms of the purified ligand peptides. The purified peptides were analyzed by reversed-phase HPLC (Hitachi La Chrom Elite, Tokyo, Japan) on a Protein-R column (Nacalai Tesque,

Kyoto, Japan) using a mobile phase consisting of acetonitrile/0.1% TFA (0% to 100% v/v) (for **1t**, **2t** and **3f**) or methanol/0.1% TFA (0% to 100% v/v) (for **1b**, **1l** and **2l**).




Figure S7. Fluorescence microscope images of RMA cells treated with TAMRA-labeled peptide **1t** (0.8 μ M) in serum-containing medium for 3 h at 37 °C. After washing three times with serum-free medium, cells were observed by fluorescence microscopy.